File: '\\swfile\EmailIn\20240321 124916 Attachment Press Release respecting SSC (E0716378x7ADBE).doc'

{E0716378.DOC; 1} 1101-1030 West Georgia Street, Vancouver

British Columbia, Canada, V6E 2Y3

Tel: (780) 466-1481 Fax: (780) 485-1490

E-mail: info@bioneutra.ca www.bioneutra.ca

BIONEUTRA GLOBAL CORPORATION ENGAGES WITH SSC ADVISORY (HONG KONG) LIMITED TO PROVIDE FINANCIAL ADVISORY AND PROJECT MANAGEMENT SERVICES

Vancouver, British Columbia - (March 21, 2024) - BioNeutra Global Corporation ("BioNeutra" or the "Company") (TSXV: BGA; OTC Pink: BGACF) is pleased to announce that it has entered into an agreement ("Agreement") with SSC Advisory (Hong Kong) Limited ("SSC") to provide the Company with a range of non-exclusive financial advisory and project management services. SSC is a Hong Kong-based financial advisory firm that provides assistance to corporations for the purpose of accessing capital markets.

Pursuant to the Agreement, SSC will identify and introduce third parties for potential equity and debt financings along with other transactional opportunities. SSC will review and advise on the overall accounting and corporate documentation of the Company. There are no specific performance obligations contained in the Agreement and SSC will not receive common shares, stock options or any form of equity in the Company as compensation.

SSC and BioNeutra are arms-length parties and SSC and its principals do not currently own or have any interest, directly or indirectly, in the securities of the Company; however, SSC and and/or its clients may acquire an interest in the securities of the Company in the future.

Dr. Jianhua Zhu, President and CEO of BioNeutra commented "We look forward to working together with SSC and having them assist us in exploring capital market initiatives and opportunities in North America for the advancement of the Company."

About BioNeutra

BioNeutra is an award-winning, sector-leading Canadian company in the business of research and development, production and commercialization of ingredients for nutraceutical, functional and mainstream foods and beverages with a focus on its lead product - VitaFiber(TM) IMO.

VitaFiber(TM) IMO is made using a patented process that naturally transforms starch molecules from agricultural crops such as pea or tapioca into healthy, functional molecules. The VitaFiber manufacturing process is based upon a natural enzymatic conversion of the molecules without any chemical modification involved making VitaFiber(TM) IMO a natural food and beverage ingredient. VitaFiber(TM) IMO is also non-GMO, vegan friendly, gluten-free, Kosher and Halal certified and available as certified organic.

VitaFiber(TM) IMO has been approved for sale by the world's top three health regulatory bodies - GRAS approved by the US Food & Drug Administration; the European Food Safety Authority and Health Canada (approved as a novel food ingredient and dietary fiber). VitaFiber(TM) IMO is a naturally sweet, low calorie alternative to sugar and is a natural source of dietary fiber and prebiotic for human digestive health. It is also helpful with weight management.

The Company's customers include a mix of small and medium businesses as well as a number of high-profile food and beverage manufacturers on four continents.

Further information about BioNeutra is available on the Company's website at www.bioneutra.ca and the SEDAR website at www.sedar.com.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information on BioNeutra, please contact:

Dr. Jianhua Zhu

President and Chief Executive Officer

Tel: (780) 466-1481 (Ext. 132)

Email: jianhua.zhu@bioneutra.ca

Forward-Looking Information

This press release may include forward-looking information within the meaning of Canadian securities legislation concerning the business of BioNeutra. Forward-looking information is based on certain key expectations and assumptions made by the management of BioNeutra. Although BioNeutra believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioNeutra can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioNeutra disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, or any applicable securities laws or any state of the United States and may not be offered or sold in the United States or to the account or benefit of a person in the United States absent an exemption from the registration requirements